Published • loading... • Updated
Development of an Investigational Epigenetic Silencer Therapy to Transcriptionally Inactivate Viral DNA in Chronic Hepatitis B
Summary by Stemwell Science News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
A treatment based on a modified version of CRISPR technology is trying to stop the activity of hepatitis B virus in the long term. Therapy has had promising results in animal experiments, but its efficacy and safety for humans has not yet been demonstrated.
Development of an Investigational Epigenetic Silencer Therapy to Transcriptionally Inactivate Viral DNA in Chronic Hepatitis B
Investigators showed that in hepatitis B virus (HBV) mouse models, a single dose of CRMA-1001, which employs an optimized epigenetic silencer that represses viral transcription, produced >3-log10 reductions in viral biomarkers, which correlated with de novo methylation of HBV DNA. [Nature Biomedical Engineering] Full ArticlePress Release
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
